Introduction
Losartan potassium, an angiotensin II receptor blocker (ARB), is a widely used medication for the treatment of hypertension and other cardiovascular conditions. This article provides an update on recent clinical trials, market analysis, and projections for losartan potassium.
Clinical Trials Update
Efficacy and Safety of Single-Pill Amlodipine/Losartan
A recent clinical trial in China compared the efficacy and safety of a single-pill combination of amlodipine and losartan (AML/LOS) versus losartan alone in patients with inadequately controlled hypertension. The study found that the AML/LOS combination was more effective in reducing both systolic and diastolic blood pressure compared to losartan alone[1].
Comparative Efficacy of Losartan and Irbesartan
Another study compared the antihypertensive efficacy and tolerability of losartan and irbesartan, another ARB. The results indicated that irbesartan at a dose of 300 mg showed greater reductions in both systolic and diastolic blood pressure compared to losartan at 100 mg[3].
Losartan in COVID-19 Patients
The CORONA II trial investigated the use of losartan in patients hospitalized for acute COVID-19. However, the trial was stopped early due to significant safety concerns, including higher rates of serious adverse events and hypotension in the losartan group compared to the usual care group[4].
Market Analysis
Global Market Size and Growth
The global losartan potassium API market is projected to grow significantly. As of 2024, the market size is estimated at USD 1652.2 million and is expected to expand to USD 2403.42 million by 2031, with a Compound Annual Growth Rate (CAGR) of 5.50% from 2024 to 2031[2].
Regional Market Share
- North America: Held the major market share of over 40% of the global revenue, with a market size of USD 660.88 million in 2024, and is expected to grow at a CAGR of 3.7% from 2024 to 2031[2].
- Europe: Accounted for more than 30% of the global revenue, with a market size of USD 495.66 million in 2024, and is expected to grow at a CAGR of 4.0% from 2024 to 2031[2].
- Asia-Pacific: Held around 23% of the global revenue, with a market size of USD 380.01 million in 2024, and is expected to grow at a CAGR of 7.5% from 2024 to 2031. This region is anticipated to be a key hub for the manufacturing and consumption of losartan potassium APIs due to its large population, rising rates of hypertension, and affordable manufacturing capabilities[2].
Other Regions
- Latin America: Held around 5% of the global revenue, with a market size of USD 82.61 million in 2024, and is expected to grow at a CAGR of 4.9% from 2024 to 2031[2].
- Middle East and Africa: Held around 2% of the global revenue, with a market size of USD 33.04 million in 2024, and is expected to grow at a CAGR of 5.2% from 2024 to 2031[2].
Market Drivers
Increasing Prevalence of Hypertension
The rising prevalence of hypertension worldwide is a significant driver for the losartan potassium market. Hypertension is a major risk factor for cardiovascular diseases, including heart attacks, strokes, and heart failure, which increases the demand for effective antihypertensive treatments[5].
Demand for Combination Therapies
The market growth is also attributed to the increasing awareness about the benefits of combination therapies. The combination of losartan with other medications, such as hydrochlorothiazide, has been shown to be effective in controlling blood pressure in patients with hypertension[5].
Technological Advancements and Patent Expirations
Technological advancements and the patent expiration of several branded losartan-hydrochlorothiazide tablet formulations are additional factors driving market growth. These developments allow for the production of generic drugs, which are more affordable and accessible to a broader population[5].
Market Projections
Forecasted Growth
The global losartan potassium API market is expected to continue its growth trajectory, driven by the increasing demand for antihypertensive treatments, especially in regions with large populations and rising rates of cardiovascular disorders. The Asia-Pacific region, in particular, is expected to witness substantial growth due to government measures to improve healthcare access and promote market expansion[2].
Regional Expansion
The market is projected to expand significantly in regions like Asia-Pacific, driven by factors such as rapid urbanization, changing lifestyles, and rising disposable incomes. These factors contribute to increased healthcare costs and a higher demand for efficient antihypertensive treatments[2].
Key Takeaways
- Clinical Efficacy: Losartan potassium, especially in combination with other medications like amlodipine, has shown superior efficacy in reducing blood pressure compared to monotherapy.
- Market Growth: The global losartan potassium API market is expected to grow from USD 1652.2 million in 2024 to USD 2403.42 million by 2031.
- Regional Trends: Asia-Pacific is anticipated to be a key region for market growth due to its large population and increasing healthcare demands.
- Market Drivers: The increasing prevalence of hypertension, demand for combination therapies, and technological advancements are significant drivers for the market.
FAQs
What is the current market size of the global losartan potassium API market?
The global losartan potassium API market size is estimated at USD 1652.2 million in 2024[2].
What is the projected growth rate of the losartan potassium API market from 2024 to 2031?
The market is expected to grow at a Compound Annual Growth Rate (CAGR) of 5.50% from 2024 to 2031[2].
Which region is expected to witness the highest growth in the losartan potassium API market?
The Asia-Pacific region is expected to witness the highest growth, driven by its large population and rising rates of hypertension and cardiovascular disorders[2].
What are the primary drivers of the losartan potassium market?
The primary drivers include the increasing prevalence of hypertension, demand for combination therapies, and technological advancements[5].
What were the findings of the CORONA II trial regarding losartan in COVID-19 patients?
The trial was stopped early due to significant safety concerns, including higher rates of serious adverse events and hypotension in the losartan group compared to the usual care group[4].
Sources
- Frontiers in Cardiovascular Medicine: "Efficacy and safety of single-pill amlodipine/losartan ... - Frontiers"
- Cognitive Market Research: "The global Losartan Potassium API market size will be USD 1652.2 ..."
- American Journal of Hypertension: "Comparative Efficacy of Two Angiotensin II Receptor Antagonists ..."
- Clinical Infectious Diseases: "Effects of Losartan on Patients Hospitalized for Acute COVID-19"
- Data Insights Market: "Losartan Potassium Hydrochlorothiazide Tablet - Data Insights Market"
